Alan Blair
Hoffmann-La Roche
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Alan Blair.
Diabetologia | 1996
Marian Rewers; Teodorica L. Bugawan; Jill M. Norris; Alan Blair; Brenda Beaty; Michelle Hoffman; R. S. McDuffie; Richard F. Hamman; Georgeanna J. Klingensmith; George S. Eisenbarth; Henry A. Erlich
SummaryAutoimmunity causing insulin-dependent diabetes mellitus (IDDM) begins in early childhood due to interactions between genes and unknown environmental factors that may be identified through follow-up of a large cohort of genetically susceptible children. Such a cohort has been established using a simple and rapid cord blood screening for HLA alleles. The DRB1 and DQB1 second exon sequences were co-amplified using the polymerase chain reaction and hybridized with single and pooled sequence-specific oligonucleotide probes. Four individual probes were used to detect the susceptibility alleles DRB1*03, DRB1*04, and DQBl*0302 as well as the usually protective DRB1*15/16 (DR2) alleles. In addition, pooled probes allow the distinction of DR3/3 from the DR3/x genotype (where x is neither DR2, 3, nor 4) and DR4/4 from DR4/x. Among 5000 newborns from the general Denver population, we have found the high-risk genotype (DRBl*03/ DRB1*04, DQBl*0302) to be present in 2.4% of non-Hispanic whites, 2.8% of Hispanics, and 1.6% of African Americans. The moderate-risk genotypes (DRB1*04, DQBl*0302/DRBl*04, DQB1*0302, DRB1*04, DQBl*0302/x, or DRBl*03/DRBl*03) are present in 17 % of American non-Hispanic whites, 24% of Hispanics and in 10% of African Americans. These results demonstrate the feasibility of a large-scale newborn screening for genes associated with IDDM. The ultimate role for such a screening in future routine prediction and prevention of IDDM will depend on the availability of an effective and acceptable form of clinical intervention.
Pediatric Diabetes | 2011
William Hagopian; Henry A. Erlich; Åke Lernmark; Marian Rewers; Anette-G. Ziegler; Olli Simell; Beena Akolkar; Robert F. Vogt; Alan Blair; Jorma Ilonen; Jeffrey P. Krischer; Jin Xiong She
Hagopian WA, Erlich H, Lernmark Å, Rewers M, Ziegler AG, Simell O, Akolkar B, Vogt Jr R, Blair A, Ilonen J, Krischer J, She J, and the TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants.
Diabetes | 2009
Andrea K. Steck; Weiming Zhang; Teodorica L. Bugawan; Katherine Barriga; Alan Blair; Henry A. Erlich; George S. Eisenbarth; Jill M. Norris; Marian Rewers
OBJECTIVE Specific alleles of non-HLA genes INS, CTLA-4, and PTPN22 have been associated with type 1 diabetes. We examined whether some of these alleles influence development of islet autoimmunity or progression from persistent islet autoimmunity to type 1 diabetes in children with high-risk HLA-DR,DQ genotypes. RESEARCH DESIGN AND METHODS Since 1993, the Diabetes Autoimmunity Study in the Young (DAISY) has followed 2,449 young children carrying HLA-DR,DQ genotypes associated with type 1 diabetes. Of those, 112 have developed islet autoimmunity (persistent autoantibodies to insulin, GAD65, and/or IA-2), and 47 of these have progressed to type 1 diabetes. The influence of polymorphisms of INS(−23Hph1), CTLA-4(T17A), and PTPN22(R620W) on development of persistent islet autoimmunity and progression to type 1 diabetes was evaluated by parametric models and by survival analyses. RESULTS PTPN22(R620W) allele T was associated with development of persistent islet autoimmunity (hazard ratio 1.83 [95% CI 1.27–2.63]) controlling for ethnicity, presence of HLA-DR3/4,DQB1*0302, and having a first-degree relative with type 1 diabetes. Survival analyses showed a significantly (P = 0.002) higher risk of persistent islet autoimmunity by age 10 years for the TT genotype (27.3%) than for the CT or CC genotype (7.9 and 5.3%, respectively). Cumulative risk of persistent islet autoimmunity was slightly higher (P = 0.02) for the INS(−23Hph1) AA genotype (7.8%) than for the AT or TT genotype (4.2 and 6.4% risk by age 10 years, respectively). CONCLUSIONS Whereas the HLA-DR3/4,DQB1*0302 genotype had a dramatic influence on both development of islet autoimmunity and progression to type 1 diabetes, the PTPN22(R620W) T allele significantly influences progression to persistent islet autoimmunity in the DAISY cohort.
Journal of Autoimmunity | 1996
Marian Rewers; Jill M. Norris; George S. Eisenbarth; Henry A. Erlich; Brenda Beaty; Georgeanna J. Klingensmith; Michelle Hoffman; Liping Yu; Teodorica L. Bugawan; Alan Blair; Richard F. Hamman; Mark R. Groshek; Robert S. McDuffie
Tissue Antigens | 2000
Teodorica L. Bugawan; William Klitz; Alan Blair; Henry A. Erlich
Diabetes | 2005
Andrea K. Steck; Teodorica L. Bugawan; Ana M. Valdes; Lisa M. Emery; Alan Blair; Jill M. Norris; Maria J. Redondo; Sunanda R. Babu; Henry A. Erlich; George S. Eisenbarth; Marian Rewers
Archive | 2005
Autoimmunity K. Steck; Teodorica L. Bugawan; Ana M. Valdes; Lisa M. Emery; Alan Blair; Jill M. Norris; Maria J. Redondo; Sunanda R. Babu; Henry A. Erlich; George S. Eisenbarth; Marian Rewers
Human Immunology | 2008
Teodorica L. Bugawan; W. Isoda; C. Mano; Alan Blair; S. Mallal; D. Thorborn; Henry A. Erlich
Human Immunology | 2010
Alan Blair; Jeff Post; Lisa M. Ide; Lavanya Nallamshetty; Maria Alejandrino; Misgana Bogale; Judy Baxter; Kathy Waugh; Kathy Barriga; Teodorica L. Bugawan; Henry A. Erlich; Marian Rewers
Human Immunology | 2008
Alan Blair; Jeff Post; Lisa M. Ide; Lavanya Nallamshetty; Maria Alejandrino; M. Bogale; Judy Baxter; K. Waugh; Teodorica L. Bugawan; Marian Rewers; Henry A. Erlich